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Abstract
Background: The aim of this individual participant data (IPD) meta-analysis is to assess whether the effects of
repeat prenatal corticosteroid treatment given to women at risk of preterm birth to benefit their babies are
modified in a clinically meaningful way by factors related to the women or the trial protocol.
Methods/Design: The Prenatal Repeat Corticosteroid International IPD Study Group: assessing the effects using the
best level of Evidence (PRECISE) Group will conduct an IPD meta-analysis. The PRECISE International Collaborative
Group was formed in 2010 and data collection commenced in 2011. Eleven trials with up to 5,000 women and
6,000 infants are eligible for the PRECISE IPD meta-analysis. The primary study outcomes for the infants will be
serious neonatal outcome (defined by the PRECISE International IPD Study Group as one of death (foetal, neonatal
or infant); severe respiratory disease; severe intraventricular haemorrhage (grade 3 and 4); chronic lung disease;
necrotising enterocolitis; serious retinopathy of prematurity; and cystic periventricular leukomalacia); use of
respiratory support (defined as mechanical ventilation or continuous positive airways pressure or other respiratory
support); and birth weight (Z-scores). For the children, the primary study outcomes will be death or any
neurological disability (however defined by trialists at childhood follow up and may include developmental delay
or intellectual impairment (developmental quotient or intelligence quotient more than one standard deviation
below the mean), cerebral palsy (abnormality of tone with motor dysfunction), blindness (for example, corrected
visual acuity worse than 6/60 in the better eye) or deafness (for example, hearing loss requiring amplification or
worse)). For the women, the primary outcome will be maternal sepsis (defined as chorioamnionitis; pyrexia after
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postnatal pyrexia).
Discussion: Data analyses are expected to commence in 2011 with results publicly available in 2012.
Background
Clinical significance of respiratory distress syndrome and
other neonatal morbidities in preterm birth
Respiratory distress syndrome, as a consequence of
immature lung development, is a complication of pre-
term birth and the major cause of early neonatal mortal-
ity and morbidity [1,2]. Infants born very preterm (less
than 32 weeks’ gestation) often require respiratory sup-
port, with significant numbers requiring assisted ventila-
tion, and 9.4% remain dependent on oxygen therapy 28
days after birth and are diagnosed with chronic lung dis-
ease [1]. Of infants born very preterm admitted for neo-
natal intensive care, a substantial proportion (21.6%) will
have an intraventricular haemorrhage (IVH) with 5.8%
being Grade 3 or 4 IVH; 1.7% will have cystic periventri-
cular leukomalacia; and 4.1% of babies will have severe
retinopathy of prematurity [1]. Children born preterm
who survive have an increased risk of re-hospitalisation
after discharge home and a recognised higher risk of
subsequent long-term neurodevelopmental impairments,
including cerebral palsy [3,4], than do children born at
term. The personal and emotional costs for affected
individuals and their families are high, as are the
immediate and long-term monetary costs of these mor-
bidities for parents and society [3-6].
Strategies to reduce the risk of neonatal respiratory
disease for preterm birth continue to receive consider-
able attention [7-9]. A single course of prenatal corticos-
teroids compared with placebo has not been shown to
be effective in babies who are born more than seven
days after treatment [7]. Specifically, there is insufficient
evidence of a reduction in the incidence of respiratory
distress syndrome or neonatal mortality [7,10,11] and
birth weight is significantly reduced [7]. This evidence
led to the suggestion [12] and uptake into clinical prac-
tice within Australia [13] and other countries [14], with
minimal formal assessment, of repeating the dose of
prenatal corticosteroids in the 34% to 40% [7,10] of
women who remained at risk of preterm birth seven or
more days after the initial course.
Observational studies, with their inherent risk of bias,
have given conflicting results, some suggesting adverse
effects of repeat corticosteroids on measures of foetal
growth [15] and on delayed development in early child-
hood [16], whilst others have indicated a possible reduc-
tion in cerebral palsy [17]. Given the need for better
quality evidence about the benefits and harms of repeat
prenatal corticosteroids, randomised clinical trials have
now been reported [18-27].
A recent Cochrane systematic review of published
aggregate data was unable to answer some important
clinical questions which this individual participant data
(IPD) meta-analysis will address [28].
Summary of the Cochrane systematic review of the
aggregate data in 2011
It remains unclear whether repeat dose(s) of prenatal
corticosteroids are beneficial. The most recent Cochrane
systematic review that assesses the use of repeat prenatal
corticosteroids for women at risk of preterm birth to
prevent neonatal respiratory disease included ten trials
(over 4,730 women and 5,650 babies) with low to mod-
erate bias [28].
Five of the trials were conducted in the US
[20,21,23,26,27]; one in each of Canada [18], India [22]
and Finland [25]; one in Australia and New Zealand
[19]; and one involved 20 countries [24].
Six trials [18,19,21-23,26] gave repeat corticosteroids
at seven day intervals if risk of preterm birth remained,
one trial [24] at 14 day intervals and three trials
[20,25,27] specifically targeted women for ‘rescue ther-
apy’ (repeat doses only given when preterm birth was
considered imminent).
There was diversity in the inclusion and exclusion cri-
teria for the ten included trials, with wide variation in
the reasons women were at risk of preterm birth (pre-
term labour, preterm prelabour rupture of the mem-
branes, antepartum haemorrhage, pre-eclampsia, foetal
growth restriction, cervical incompetence and multiple
pregnancy); the gestational age women were eligible
(from 24 to 34 weeks); and the time of treatment prior
to expected preterm birth. All women received a single
course of prenatal corticosteroids one week or more
before trial entry. However, the type, amount and timing
regimen for administration of the corticosteroid given
before the trial varied between trials.
Treatment of women who remain at risk of preterm
birth seven or more days after an initial course of prena-
tal corticosteroids with repeat dose(s), compared with
no repeat corticosteroid treatment, reduced the risk of
their infants being affected by the primary outcomes,
respiratory distress syndrome (risk ratio (RR) 0.83, 95%
confidence interval (CI) 0.75 to 0.91; eight trials; 3,206
infants; numbers needed to treat (NNT) 17, 95% CI 11
to 32) and serious infant outcome (RR 0.84, 95% CI 0.75
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Treatment with repeat dose(s) of corticosteroid was
associated with a reduction in mean birth weight (mean
difference -75.8 g, 95% CI -117.6 g to -34 g; nine trials;
5,626 infants). However, outcomes that adjusted birth
weight for gestational age (birth weight Z-scores, birth
weight multiples of the median and small for gestational
age) did not differ between treatment groups.
At early childhood follow-up, no statistically signifi-
cant differences were seen for infants exposed to repeat
prenatal corticosteroids compared with unexposed
infants for the primary outcomes, total deaths (RR 0.98,
95% CI 0.72 to 1.33; two trials; 3,250 infants), survival
free of any disability (RR 1.00, 95% CI 0.97 to 1.04; two
trials; 3,164 infants), survival free of major disability (RR
0.77, 95% CI 0.55 to 1.08; one trial; 999 infants), disabil-
ity (RR 0.98, 95% CI 0.83 to 1.16; one trial; 999 infants)
or serious outcome (RR 0.99, 95% CI 0.87 to 1.12; two
trials; 3164 infants), or in the secondary outcome
growth assessments [28].
For maximising benefit and minimising harm, many
questions remain. How can the potentially important
benefits observed be applied to individual women who
have different reasons for, and levels of risk, of preterm
birth? If repeat prenatal corticosteroids are to be recom-
mended, what are the optimal gestational ages for
administration, the optimal number of repeat treatments
that should be given, and at what dose and timing? Indi-
vidual participant meta-analysis of the data from the 11
trials now available may help to answer these questions.
Overcoming limitations: conducting an individual
participant data meta-analysis
Analysis of thoroughly checked and updated data from
individual participants in all the available randomised
trials has been described as the gold standard in sys-
tematic reviews [29]. Estimates of treatment effects are
often different from those obtained from aggregate pub-
lished data due to inclusion of additional or updated
data. The methods and advantages of IPD review have
been well described [30,31].
An integral component of conducting an IPD meta-
analysis is the formation of an international collabora-
tive group of trialists where all researchers endorse the
IPD protocol and provide data from their trials. This
generates additional benefits that include more complete
identification of trials and of trial details; compliance
with standard definitions; provision of missing data on
characteristics of trials, all women who were randomised
and their babies, and outcomes; more balanced interpre-
tation, endorsement and global dissemination of results;
and better clarification and consensus on future research
needed with the opportunity for on-going international
collaborations [32].
Objectives
Our aim is to assess, using IPD meta-analyses, the
effects on important clinical outcomes of repeat pre-
natal corticosteroid treatment given to women at risk
of preterm birth to benefit their babies, both short-
term and long-term, and whether treatment effects
differ in a clinically meaningful way between impor-
tant pre-specified participant-level and trial-level
characteristics.
Research Questions
For maximising benefit and minimising harm, the main
research questions to be addressed in this review are:
1. Are repeat prenatal corticosteroids more effective
in some women by reason of their risk of preterm
birth?
2. If the use of repeat prenatal corticosteroids is
recommended, what is the best gestational age to
maximise benefit?
3. What dose, number of repeat doses and timing
prior to birth is optimal?
4. What is the minimal effective and safe dose of
repeat prenatal corticosteroids?
5. Is a single rescue steroid dose effective?
Methods/Design
Study design
IPD meta-analysis.
Inclusion and exclusion criteria for the studies
Studies, published or unpublished, will be included if
they were randomised trials with adequate allocation
concealment and report data on one or more of the
pre-stated outcomes. Quasi-random study designs will
not be included. As of September 2011, 11 trials with
up to 5,000 women and 6,000 infants are eligible for
the Prenatal Repeat Corticosteroid International IPD
Study Group: assessing the effects using the best level
of Evidence (PRECISE) IPD meta-analysis [18-27,33]
(Table 1).
Eligibility of trials will be assessed independently and
unblinded for author and journal by two members of
the PRECISE IPD Project Team. Any differences in opi-
nion regarding eligibility will be resolved by discussion.
If IPD are unavailable for any eligible trial, the trial will
still be included in the review and aggregate data will be
used for sensitivity analyses wherever possible.
Types of participants
Women considered at risk of preterm birth (< 37 weeks
gestation) who have already received a single course of
prenatal corticosteroid seven or more days previously.
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Corticosteroid administered to the women intrave-
nously, intramuscularly or orally, compared with either
placebo or no placebo. Trials in which the foetus
received corticosteroids directly will not be included.
Search strategy to identify potential trials
We will use the search strategy developed by the
Cochrane Pregnancy and Childbirth Review Group for
the Cochrane review, which identifies trials from quar-
terly searches of the Cochrane Central Register of Con-
trolled Trials (CENTRAL); weekly searches of
MEDLINE; hand searches of 30 journals and the pro-
ceedings of major conferences; weekly current awareness
alerts for a further 44 journals plus monthly BioMed
Central email alerts.
We will also search CENTRAL, MEDLINE and
EMBASE to identify trials published since the search
cut-off date of 31 August 2008 for the Cochrane review;
using the terms [repeat or multiple] and [antenatal or
prenatal] and [corticosteroid* or steroid* or glucocorti-
coid* or betamethason* or dexamethason* or
hydrocortison*].
In addition we will access Current Controlled Trials
http://www.controlled-trials.com and the Australian and
New Zealand Trials Register http://www.anzctr.org.au to
identify recently completed or on-going trials.
Experts in the field and trialists will be asked if they
know of any unpublished or other trials.
Data collection and management
Data collected will include all women randomised and
coded for anonymity (date of birth, centre identifica-
tion); baseline data for descriptive purposes and analyses
(reason at risk of preterm birth, gestational age at trial
entry, plurality of the pregnancy, expected date of birth);
details of the intervention given (date of randomisation,
allocated intervention, type and dose of corticosteroid
given, interval between treatments, whether re-treatment
given and amount); and outcomes, to allow planned
analyses.
Trialists will provide de-identified IPD in any conveni-
ent format by encrypted, electronic transfer where possi-
ble or other means as needed. The individual trial data
will be recoded as required and stored in a custom
designed secure database which will only be accessible
by authorised personnel of the PRECISE Data Manage-
ment Group. Trialists will be asked to verify all recoded
data prior to any analysis and the data will not be used
f o ra n yo t h e rp u r p o s ew i t h o u tp e r m i s s i o no fa l l
collaborators.
The data will be checked with respect to range, inter-
nal consistency, missing or extreme values, errors and
consistency with published reports. Trial details, such as
randomisation methods, and intervention details will be
cross-checked against published reports, trial protocols
and data collection sheets. Inconsistencies or missing
data will be discussed with the individual trialists and
attempts will be made to resolve any problems by
Table 1 Eligible trials with their inclusion criteria and corticosteroid regimens as at September 2011
TRIAL Gestational age at
entry (weeks)
Repeat corticosteroid timing Repeat corticosteroid regimen Number of
repeat courses
Garite 2009
[20]
25 to < 33 Birth expected < 7 days 2 × 12 mg betamethasone 24 hours apart; or 4 ×
6 mg dexamethasone 12 hours apart
1
Peltoniemi
2007 [25]
< 34 Birth expected < 48 hours 1 × 12 mg betamethasone 1
Aghajafari
2002 [18]
24 to 30 Weekly until 33 weeks, or birth if still
at risk of preterm birth
2 × 12 mg betamethasone 24 hours apart varied
Crowther
2006 [19]
< 32 Weekly until < 32 weeks, and if still at
risk of preterm birth
1 × 11.4 mg betamethasone varied
Guinn 2001
[21]
24 to < 33 Weekly until 34 weeks 2 × 12 mg betamethasone 24 hours apart varied
Mazumder
2008 [22]
26 to 33 Weekly until < 34 weeks 2 × 12 mg betamethasone 24 hours apart varied
McEvoy
2002 [23]
25 to 33 Weekly until 34 weeks 2 × 12 mg betamethasone 24 hours apart varied
McEvoy
2010 [27]
26 to 34 Rescue course 14 days after initial
dose; < 34 weeks
2 × 12 mg betamethasone 24 hours apart 1
Murphy
2006 [24]
25 to 32 Fortnightly until 33 weeks 2 × 12 mg betamethasone 24 hours apart varied
Wapner
2006 [26]
23 to < 32 Weekly until < 34 weeks 2 × 12 mg betamethasone; 24 hours apart varied
Brocklehurst
[14]
< 32 Weekly (with 10 and 14 day intervals
being used in some centres)
2 × 12 mg betamethasone; 12 or 24
hours apart.
varied
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the trial data will be sent to the trialists for verification.
Data items to be collected
Trial level information 1. Dates the trial opened and
closed accrual
2. Number of participants randomised
3. Informed consent procedures
4. Methods of random allocation
5. Stratification factors
6. Methods of allocation concealment
7. Blinding procedures for outcome assessment
8. Purpose repeat corticosteroid treatment given (pro-
phylaxis against preterm birth; ‘rescue therapy’ when
preterm birth is imminent; other)
9. Details of the planned intervention in the experi-
mental arms (drug frequency; timing; doses):
a. Type of repeat prenatal corticosteroid treatment
given
b. Number of repeat doses planned to be given
c. Minimum planned interval between the initial cor-
ticosteroid and the repeat dose
d. Minimum planned interval between repeat steroid
treatments
e. Planned dose of corticosteroid to be given per
repeat treatment
f. Planned dose of repeat steroid drug exposure per
week
g. Total drug exposure planned
10. Details of the planned intervention in the control
arm
Participant-level information - maternal characteris-
tics at study entry 1. Unique identification coded for
anonymity
2. Maternal age
3. Body mass index
4. Parity
5. Ethnicity
6. Public or private patient
7. Previous obstetric history
8. Reason the woman was considered to be at risk of
preterm birth (preterm labour; presence or absence of
ruptured membranes; antepartum haemorrhage; pre-
eclampsia or eclampsia; foetal growth restriction; sus-
pected foetal jeopardy; cervical incompetence; maternal
disease; multiple pregnancy)
9. Pre-trial treatment with corticosteroids (gestation
dose given; corticosteroids used; dose regimen)
10. Reason repeat prenatal corticosteroid treatment
was considered (prophylaxis against preterm birth; ‘res-
cue therapy’ when preterm birth is imminent; other)
11. Number of foetuses in utero
Participant-level information - maternal information
after trial entry 1. Gestational age when repeat prenatal
corticosteroid treatment was started
2. Time prior to birth repeat prenatal corticosteroid
treatment was given
3. Adverse events for the woman at time of treatment
4. Antenatal information after trial entry
5. Intrapartum information
6. Postnatal information
Participant-level information - data on actual study
intervention relating to regimens 1. Type of repeat
prenatal corticosteroid treatment given
2. Number of repeat doses actually given
3. Minimum actual interval between the initial corti-
costeroid and the study repeat dose
4. Minimum actual interval between repeat steroid
treatments
5. Actual dose of corticosteroid given per repeat
treatment
6. Actual dose of repeat steroid drug exposure per
week
7. Total actual drug exposure
8. Actual rescue treatment versus weekly treatment
Participant-level information - neonatal information
1. Unique baby identification and mother identification
coded for anonymity
2. Date and time of birth
3. Gestational age at birth
4. Gender
5. Mode of birth
6. Birth weight, length, head circumference
7. Apgar score at 1 and 5 minutes
8. Neonatal complications and/or status
9. Mortality and age at death
10. Cause of death
11. Childhood follow-up assessments
Planned analyses
A detailed statistical analysis plan will be prepared by
the PRECISE Data Management Group and agreed
upon by the PRECISE IPD Project Team and the PRE-
CISE International IPD Study Group prior to the data
analyses. Any analyses conducted will be based on the
checked and updated individual participant data from
all available trials. All randomised participants with
outcome data available will be included in the ana-
lyses, which will be performed on an intention to treat
basis, according to the treatment allocation at
randomisation.
For each of the outcomes, a one-stage approach to
analysis will be taken so that the IPD from all eligible
trials are included in a single model [34]. Fitting a single
model for each outcome variable will enable the varia-
tion across trials to be accounted for within the model
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interaction term will be tested to assess heterogeneity of
treatment effect across trials. If excessive statistical het-
erogeneity in treatment effect or inconsistency across
trials is detected (that is, if the trial by treatment inter-
action term is significant), then the rationale for com-
bining trials will be questioned and the source of
heterogeneity explored.
Binary outcomes will be analysed using log binomial
regression models and results will be presented as risk
ratios with 95% CI and associated two-sided P values.
Continuous outcomes will be analysed using linear
regression models and results will be presented as differ-
ences in means with 95% CI and two-sided P values.
Correlation between outcomes due to multiple births
will be taken into account using generalised estimating
equations as appropriate.
Any differences in treatment effect between pre-speci-
fied subgroups will be assessed by testing a treatment by
subgroup interaction term within the model [35].
Outcomes
Outcomes have been chosen to be most representative
of the clinically important measures of effectiveness and
safety, including serious outcomes, for the women and
their babies. The definitions given by the trialists are
used unless otherwise stated.
Primary outcomes
For the infants 1. serious outcome, defined by the PRE-
CISE International IPD Study Group as one of death
(foetal, neonatal or infant), severe respiratory disease,
severe IVH (grade 3 and 4), chronic lung disease (oxy-
gen dependent at 36 weeks postnatal age), definite
necrotising enterocolitis, severe retinopathy of prematur-
ity (Stage 3 or worse in the better eye) or cystic periven-
tricular leukomalacia
2. use of respiratory support, defined as mechanical
ventilation or continuous positive airways pressure or
other respiratory support
3. birth weight (Z-scores) [36].
For the children 1. death or any neurosensory disability
at childhood follow up, and may include developmental
delay or intellectual impairment (developmental quoti-
ent or intelligence quotient more than one standard
deviation below the mean), cerebral palsy (abnormality
of tone with motor dysfunction), blindness (for example,
corrected visual acuity worse than 6/60 in the better
eye) or deafness (for example, hearing loss requiring
amplification or worse).
For the women 1. maternal sepsis, defined as chorioam-
nionitis during labour, pyrexia after trial entry requiring
the use of antibiotics, puerperal sepsis, intrapartum
fever requiring the use of antibiotics or postnatal
pyrexia.
Secondary outcomes
For the infants 1. foetal, neonatal or later death (up to
primary hospital discharge)
2. severe respiratory disease
3. severe IVH (grade 3 and 4)
4. chronic lung disease
5. necrotising enterocolitis
6. retinopathy of prematurity
7. cystic periventricular leukomalacia
8. respiratory distress syndrome
9. IVH
10. patent ductus arteriosus
11. neonatal encephalopathy
12. serious outcome (may include: foetal, neonatal or
later death; respiratory distress syndrome; severe lung
disease; chronic lung disease; intraventricular haemor-
rhage; patent ductus arteriosus; neonatal encephalopa-
thy; retinopathy of prematurity)
13. gestational age at birth (actual gestational age, pre-
term birth less than 37 weeks, very preterm birth less
than 32 weeks and extremely preterm birth less than 28
weeks)
14. interval between trial entry and birth
15. small-for-gestational age [36]
16. birth weight (raw values)
17. head circumference at birth (raw values and Z-
scores) [36]
18. length at birth (raw values and Z-scores) [36]
19. placental weight
20. Apgar score less than seven at five minutes
21. resuscitation at birth
22. duration of respiratory support
23. use of oxygen supplementation
24. duration of oxygen supplementation
25. use of surfactant
26. air leak syndrome
27. pulmonary hypertension
28. use of inotropic support
29. use of nitric oxide for respiratory support
30. early neonatal infection
31. proven neonatal infection while in the neonatal
intensive care unit
32. use of postnatal corticosteroids
33. neonatal blood pressure (systolic, diastolic and
mean arterial blood pressure)
34. growth assessments at primary hospital discharge
(Z-scores for weight, head circumference, length) [36]
35. hypothalamic/pituitary/adrenal axis suppression.
For the children (follow up) Categories will be col-
lapsed and/or combined where data are insufficient:
1. death (foetal, neonatal or later death up to the time
of follow up)
2. neurosensory impairments
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or severe)
b. developmental delay or intellectual impairment
(categorised as nil, mild (< 85), moderate (< 70) or
severe (< 55))
c. blindness
d. deafness
e. gross motor dysfunction, defined as mild, moder-
ate or severe, by trialists or by the Gross Motor
Classification System (score 1 to 5), if available
f. motor delay (categorised as nil, mild (< 85), mod-
erate (< 70) or severe (< 55) by appropriate mode of
assessment)
3. any neurosensory disability, defined as developmen-
tal delay or intellectual impairment (developmental quo-
tient or intelligence quotient more than one standard
deviation below the mean), cerebral palsy (abnormality
of tone with motor dysfunction), blindness or deafness,
at follow up later in childhood
4. major neurosensory disability, defined as any mod-
erate or severe neurosensory impairment
5. survival free of major neurosensory disability (alive
and without major disability)
6. growth assessments at childhood follow up (Z-
scores for weight, head circumference, height) [37]
7. child behaviour
8. child temperament
9. respiratory disease
10. blood pressure.
For the women 1. chorioamnionitis during labour
2. pyrexia after trial entry requiring the use of
antibiotics
3. puerperal sepsis
4. intrapartum fever requiring the use of antibiotics
5. postnatal pyrexia
6. death
7. preterm prelabour rupture of the membranes after
trial entry
8. hypertension
9. mode of birth (normal vaginal birth, operative vagi-
nal birth, Caesarean section)
10. postpartum haemorrhage
11. breastfeeding at hospital discharge
12. postnatal depression
13. adverse effects of corticosteroid therapy (including
gastrointestinal upset, glucose intolerance, insomnia,
pain at the injection site, bruising at the injection site,
infection at injection site, weight gain, Cushing
appearance).
Use of health services 1. length of antenatal hospitalisa-
tion for the women
2. length of postnatal hospitalisation for the women
3. maternal admission to intensive care unit
4. admission to neonatal intensive care unit
5. length of stay in neonatal intensive care unit
6. length of neonatal hospitalisation.
Planned subgroup analyses
Where sufficient data exist, subgroup comparisons will
be conducted using the five infant, child and maternal
primary outcomes, as well as the individual components
of each composite outcome. Any differences in treat-
ment effect between subgroups will be assessed by test-
ing a treatment by subgroup interaction term within the
model. Some subgroups may be combined if data are
insufficient.
Subgroups
Trial-level characteristics 1. Type of repeat prenatal
corticosteroid treatment given (betamethasone or
dexamethasone).
2. Number of repeat doses planned to be given.
3. Minimum planned interval between the initial corti-
costeroid and the first repeat dose.
4. Minimum planned interval between repeat steroid
treatments.
5. Planned dose of corticosteroid per repeat treatment.
6. Planned dose of repeat steroid drug exposure per
week.
7. Total dose of repeat steroid drug planned.
Participant-level characteristics 1. Reason the woman
was considered to be at risk of preterm birth (preterm
labour, the presence or absence of ruptured membranes,
antepartum haemorrhage, pre-eclampsia and/or eclamp-
sia, foetal growth restriction, suspected foetal jeopardy,
cervical incompetence, maternal disease and multiple
pregnancy).
2. Purpose trial treatment given (prophylaxis against
preterm birth; ‘rescue therapy’ when preterm birth is
imminent; other).
3. Number of foetuses in utero (singleton versus
multiple).
4. Gestational age when first trial treatment was given
(< 26; 26 to < 28; 28 to < 30; 30 to < 32; 32 to < 34
completed weeks at randomisation).
5. Time prior to birth last dose of trial treatment was
given (< 1; 1 to < 2; 2 to < 4; 4 to < 7; 7 to < 10; 10 to
< 14; ≥ 14 days).
6. Actual rescue treatment versus weekly treatment.
Additional exposure analyses
1. Number of repeat doses actually given.
2. Minimum actual interval between the initial corti-
costeroid and the first trial treatment.
3. Minimum actual interval between repeat trial
treatments.
4. Actual dose of trial treatment given per repeat
treatment.
5. Actual dose of repeat trial treatment exposure per
week.
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Planned sensitivity analyses
To assess whether the results are robust to trial design
and quality, the following sensitivity analyses will be per-
formed on the primary outcomes, as well as the indivi-
dual components of each composite outcome (unless
otherwise specified): exclusion of trials with small sam-
ple size (less than 100 study participants); exclusion of
trials with high rate of missingness and/or exclusions
where the losses are considered to have the potential to
impact on the results; inclusion of aggregate data from
trials where individual participant data are unavailable;
exclusion of trials where not all variables used to define
the outcome were collected (composite outcomes only);
and random effects models with trial included as a ran-
dom effect (all primary and secondary outcomes).
Multiple comparisons
A large number of outcomes are being investigated in
this study, which increases the chance of observing ‘false
positive’ results. However, all outcomes are important in
giving a full clinical picture that considers the benefits
and risks to both mothers and infants. We do not plan
formal statistical adjustment of P values to account for
multiple comparisons due to the non-independence of
outcomes in this study. Results will be interpreted with
caution.
Ethics and management issues
Ethical considerations Participants in the individual
trials have previously given informed consent to partici-
pate in their respective trial. The data for this project
a r et ob eu s e df o rt h ep u r p o s ef o rw h i c ht h e yw e r eo r i -
ginally collected and are available through an agreement
between all trialists of the collaborative group. These tri-
alists remain the custodian of their original individual
trial data at all times.
Project Management
For the purpose of this project, an international Colla-
borative Group, The PRECISE Group, will manage the
project and consists of groups with specific responsibil-
ities and tasks:
The PRECISE IPD Project Team The PRECISE IPD
Project Team is the Steering Group which is responsible
for the project’s management decisions and the daily
management of the Collaboration. The Project Team’s
tasks are to design the project’s protocol and analysis
plan, organise The PRECISE Group Meetings and act as
a liaison between all the members of The PRECISE
Group. The PRECISE IPD Project Team will meet regu-
l a r l ye v e r yt w ot of o u rm o n t h s ,u s u a l l yb y
teleconference.
The PRECISE Trialist Group Members of The PRE-
CISE Trialist Group will be representatives of the eligi-
ble trials. For each trial, the first author will be invited
to become a member of the Collaboration. If considered
necessary or if there is no response from the first
author, other investigators from the trials may be con-
tacted (for example, the data manager or statistician). In
order to keep The PRECISE Trialist Group updated,
authors of new trials or previously unidentified trials
will be contacted and invited to join the Collaboration
in the course of the project.
The Data Management Group and PRECISE IPD
Statistical Team The data management group will be
convened by the Chair of The PRECISE IPD Project
Team and comprises statisticians from the data manage-
ment centre and participating trials who will conduct
the analyses. The data management group will be
responsible for the storage and analyses of the IPD pro-
ject data.
The PRECISE Group Meetings
Collaborative group face-to-face meetings will be orga-
nised at least twice during the study. Representatives of
all eligible trials will be invited to attend those meetings.
The meetings will be scheduled, if possible, in conjunc-
tion with international conferences. During those meet-
ings, various aspects of the project will be discussed
with all the collaborators, such as the project’sd e s i g n
and conduct, the analysis plan and the interpretation
and reporting of the results. The final collaborators’
meeting is scheduled for 2012.
Publication of results
The final results of the study will be presented to the
collaborators for discussion. The main manuscript will
be prepared by The PRECISE IPD Project Team and
Data Management Group and circulated to The PRE-
C I S EG r o u pf o rc o m m e n ta n dr e v i s i o n .T h er e v i s e d
draft paper will be circulated for final comment and
agreement prior to publication. PRECISE publications
arising from these data will be authored with members
of The PRECISE Group named where possible and on
behalf of The PRECISE Collaboration as a whole. The
names of all other collaborators participating will be
acknowledged within the manuscript.
Discussion
The recently updated meta-analysis [28] showed that the
short term benefits seen for babies support the use of
repeat dose(s) of prenatal corticosteroids for women
who have received an initial course of prenatal corticos-
teroids seven of more days previously and who remain
at risk of preterm birth.
For maximising benefit and minimising harm, many
questions remain. Are repeat prenatal corticosteroids
more effective in some women by reason of their risk of
preterm birth? If the use of repeat prenatal corticoster-
oids is recommended, what is the best gestational age to
use for benefit? What dose, number of repeat doses and
timing prior to birth is optimal?
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to utilise existing IPD from all women and babies
enrolled in previous trials of repeat prenatal corticos-
teroids. This approach has been described as the ‘gold
standard’ of systematic review methodology as it
allows for more powerful and flexible analysis of both
subgroups and outcomes. The PRECISE Group has
been formed to undertake a meta-analysis based on
IPD, to answer these important clinical questions. Pro-
vision of data by the participating collaborators com-
menced in 2010 and results will be ready for
presentation in 2012.
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